SCHEMBL659238

SCHEMBL659238

CCc1nc2cccc(OCc3ccccc3)c2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
DDAH1 O94760 1/20 0.46
DCPS Q96C86 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
STAT3 P40763 1/20 0.46
HTT P42858 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ADORA3 P0DMS8 1/20 0.43
SGMS2 Q8NHU3 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
BRD4 O60885 1/20 0.42
LMNA P02545 1/20 0.42
LIPE Q05469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9528108 0.86 DCPS (0.46) L3MBTL1MAPTMAPK1TDP1DCPS
SCHEMBL7619113 0.83 L3MBTL1 (0.54) L3MBTL1MAPTMAPK1TDP1DCPS
SCHEMBL7685881 0.82 RAB9A (0.60) L3MBTL1MAPTMAPK1TDP1SMN1; SMN2
SCHEMBL7690186 0.80 RAB9A (0.60) L3MBTL1MAPTTDP1SMN1; SMN2HTT
SCHEMBL9527738 0.78 PDE5A (0.51) L3MBTL1MAPTMAPK1TDP1DDAH1
SCHEMBL10535545 0.73 MAPT (0.49) L3MBTL1MAPTMAPK1TDP1SMN1; SMN2
SCHEMBL9528492 0.72 MAPT (0.54) L3MBTL1MAPTMAPK1TDP1DCPS
SCHEMBL9529350 0.72 MAPT (0.50) L3MBTL1MAPTMAPK1TDP1DCPS
SCHEMBL9528423 0.71 MAPT (0.53) L3MBTL1MAPTMAPK1TDP1SMN1; SMN2
SCHEMBL2900206 0.71 DDAH1 (0.55) L3MBTL1DDAH1SMN1; SMN2HTTTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120283260-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA ASTELLAS PHARMA INC. (JP) 2012-11-08 US disclosed
US-8252793-B2 Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma ALCON RESEARCH, LTD. (US) 2012-08-28 US disclosed
WO-2012024419-A2 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA ALCON RESEARCH, LTD. (US) 2012-02-23 WO disclosed
US-20120046285-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
EP-0266326-B1 NOVEL DERIVATIVES OF BENZIMIDAZOLES ACTIVE AS ANTI-ULCER AGENTS Aktiebolaget Hässle (SE) 1993-03-10 EP disclosed
US-5106862-A DERIVATIVES OF BENZIMIDAZOLES ACTIVE AS ANTI-ULCER AGENTS AKTIEBOLAGET HASSLE (SE) 1992-04-21 US disclosed
EP-0266326-A1 Novel derivatives of benzimidazoles active as anti-ulcer agents Aktiebolaget Hässle (SE) 1988-05-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283260-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA BDKRB2, BDKRB1, PTGIR L3MBTL1 4478/4885MAPT 2300/4885MAPK1 740/4885
US-20120046285-A1 BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA BDKRB2, BDKRB1, PTGIR L3MBTL1 4478/4885MAPT 2300/4885MAPK1 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.